Dual inhibition of ATR and PARP reverses acquired PARP inhibitor resistance in triple negative breast cancer
{{output}}
Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi) have attracted significant attention in triple negative breast cancer (TNBC) treatment. However, the acquired or de novo PARP inhibitor resistance limits treatment success. Ataxia telangiectasia and Rad3-re... ...
